Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151775 · ClinicalTrials.gov registry record · Phase 2
Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 362
- Enrollment target
NCT00151775: Completed Phase 2 study, sponsored by Daiichi Sankyo.
NCT00151775 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 362 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (172% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00151775, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 362 participants
- Enrollment target
Study Summary
This study assesses the efficacy and safety of olmesartan medoxomil in children ages 1-16 with high blood pressure. After a 5-week blinded treatment period of up to 5 weeks participants can continue to take olmesartan medoxomil (OM) for up to an additional 46 weeks.
Primary Outcome
The efficacy dose response change in trough seated systolic blood pressure (both non-weight adjusted and weight adjusted results) from baseline to the end of the dose-ranging period (Period 2). Non-weight adjusted dose was the fixed olmesartan medoxomil dose; weight adjusted dose calculated mg of olmesartan medoxomil per kg of weight at baseline.
Interventions
- DRUG placebo
- DRUG olmesartan medoxomil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
What the finished NCT00151775 record still lists
NCT00151775 is an interventional study that assigns participants to a tested intervention. The registered 362 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (172% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00151775 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00151775 about?
NCT00151775 is a clinical study titled "Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure". This study assesses the efficacy and safety of olmesartan medoxomil in children ages 1-16 with high blood pressure. After a 5-week blinded treatment period of up to 5 weeks participants can continue to take olmesartan medoxomil (OM) for up to an additional 46 weeks.
What is the current status of trial NCT00151775?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 362 participants. The study started on 2005-05. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00151775?
The interventions under investigation include: placebo (DRUG), olmesartan medoxomil (DRUG).
Who is sponsoring clinical trial NCT00151775?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00151775's enrollment target sits among peer trials
362 122nd of 2000 higher than 1,878 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04988555 · 362 participants · Phase 1
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
- NCT05536141 · 362 participants · Phase 1
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- NCT06534983 · 362 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
- NCT06472245 · 363 participants · Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia